Wall Street consensus ratings for CRISPR Therapeutics AG (NASDAQ: CRSP) generally lean toward a Hold to moderate Buy, as analysts balance its pioneering position in gene-editing technologies and clinical-stage therapeutic approvals against commercialization timelines and ongoing R&D expenses. What are your primary investment goals and portfolio risk parameters? Consulting a licensed financial advisor is recommended before making portfolio adjustments.